Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 2:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 53 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Corneal Collagen Cross-linking Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

NCT03442751
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
Test Article A, Test Article B, Placebo, KXL medical device system
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years to 55 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 3, 2026, 2:10 PM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus

NCT00925327
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
Corneal collagen cross-linking with riboflavin/UVA light
Other
Lead sponsor
Peschke Meditrade, GmbH
Industry
Eligibility
6 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2009 · Synced Oct 3, 2026, 2:10 PM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus

NCT05314738
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
NXL Energy 1, NXL Energy 2, NXL Energy 3, Sham Treatment
Combination Product
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Dothan, Alabama • Teaneck, New Jersey • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

NCT04667572
View directory record Official record
Conditions
Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Degeneration, Corneal Ectasia
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Cornea Associates of Texas
Other
Eligibility
8 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 3, 2026, 2:10 PM EDT
Withdrawn Not applicable Interventional

Higher Irradiance in Keratoconus Ectasia

NCT01789333
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
UVA Light with irradiance exposure of 9 mW/cm2, Riboflavin 0.1% ophthalmic solution
Device · Drug
Lead sponsor
Stephen Trokel
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 3, 2026, 2:10 PM EDT
Terminated Phase 2 Interventional

CXL-04 A Study of Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

NCT01956474
View directory record Official record
Conditions
Keratoconus
Interventions
Theralight crosslinking and Riboflavin
Other
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
1,324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Miami, Florida • Atlanta, Georgia • Rockville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

NCT02863809
View directory record Official record
Conditions
Keratolysis
Interventions
Riboflavin, Dextran, UVA Light Source
Drug · Device
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 3, 2026, 2:10 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking

NCT06235567
View directory record Official record
Conditions
Keratoconus
Interventions
Dextenza 0.4Mg Ophthalmic Insert, topical prednisolone acetate 1% (PredForte) eye drops
Drug
Lead sponsor
Maanasa Indaram, MD
Other
Eligibility
13 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 3, 2026, 2:10 PM EDT
Not listed Phase 3 Interventional

Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia

NCT01112072
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 3, 2026, 2:10 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL

NCT05136924
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo, Placebo (vehicle) nasal spray
Drug · Other
Lead sponsor
Vance Thompson Vision - MT
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 3, 2026, 2:10 PM EDT
Not listed Phase 3 Interventional

Corneal Cross-Linking Comparing Variables

NCT02095730
View directory record Official record
Conditions
Unstable Corneas
Interventions
Epithelium-On Riboflavin, Epithelium-Off Riboflavin, UV Light - Continuous Beam, UV Pulsed Beam
Drug · Device
Lead sponsor
Crowd Health Research, LTD
Other
Eligibility
12 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
16
States / cities
Santa Rosa, California • Denver, Colorado • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 3, 2026, 2:10 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

McNeel Eye Center Corneal Crosslinking Study

NCT02921009
View directory record Official record
Conditions
Keratoconus
Interventions
Crosslinking using UV light of two different fluence rates
Device
Lead sponsor
McNeel Eye Center
Industry
Eligibility
15 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 3, 2026, 2:10 PM EDT
Terminated Phase 3 Interventional Results available

Safety Study of the VEGA UV-A System to Treat Keratoconus

NCT01190306
View directory record Official record
Conditions
Keratoconus
Interventions
The VEGA UV-A Illumination System, Riboflavin
Device · Drug
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
12 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Phoenix, Arizona • Atlanta, Georgia • Bloomington, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Corneal Collagen Cross-linking for Progressive Keratoconus

NCT00647699
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
riboflavin ophthalmic solution, UVA Irradiation
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
14 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
La Jolla, California • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 3, 2026, 2:10 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Treatment of Keratoconus Using Collagen Cross-Linking

NCT00841386
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin-5-phosphate, Sham cross-linking
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
16 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Amherst, New York • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2009 · Synced Oct 3, 2026, 2:10 PM EDT
Not listed Phase 3 Interventional

Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin

NCT01152541
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin/Dextran, Hypotonic Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus

NCT01344187
View directory record Official record
Conditions
Keratoconus
Interventions
riboflavin solution, placebo solution, KXL System
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
10
States / cities
Irvine, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 3, 2026, 2:10 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

NCT01325298
View directory record Official record
Conditions
Keratoconus, Ectasia, Corneal Ectasia
Interventions
UV-X Light, Riboflavin
Device · Drug
Lead sponsor
Mercy Center for Corrective Eye Surgery
Other
Eligibility
14 Years to 55 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
McHenry, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 3, 2026, 2:10 PM EDT
Not listed Phase 3 Interventional

The Effects of Corneal Collagen Cross-linking

NCT01708538
View directory record Official record
Conditions
Corneal Ectasia Disorders Including Keratoconus
Interventions
CXL
Drug
Lead sponsor
Rush Eye Associates
Other
Eligibility
10 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia

NCT01143389
View directory record Official record
Conditions
Keratoconus, Post-Refractive Ectasia
Interventions
Riboflavin, UVX light
Drug · Device
Lead sponsor
Price Vision Group
Industry
Eligibility
10 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 3, 2026, 2:10 PM EDT
Withdrawn Phase 1Phase 2 Interventional

PXL-Platinum 330 in Eyes With Corneal Thinning Conditions

NCT05489510
View directory record Official record
Conditions
Corneal Thinning, Keratoconus
Interventions
Pulsed or continuous lighting
Combination Product
Lead sponsor
Vishal Jhanji
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection

NCT02068430
View directory record Official record
Conditions
Corneal Ulcers
Interventions
Riboflavin 0.1%, UV-X™ Illumination System
Drug · Other
Lead sponsor
Stephen Trokel
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 3, 2026, 2:10 PM EDT
Not listed Phase 2Phase 3 Interventional

Collagen Cross-Linking for Keratoconus/Ectasia With and Without Intacs

NCT01081561
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Yaron S. Rabinowitz M.D.
Other
Eligibility
21 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 3, 2026, 2:10 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light

NCT05027295
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
riboflavin ophthalmic solution
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 3, 2026, 2:10 PM EDT